Eli Lilly and Co. is seeking to revoke a patent held by a Johnson & Johnson unit, arguing at a London court it might delay availability of a potential treatment for Alzheimer’s disease.
Federal regulators are pressing the Supreme Court to stop big pharmaceutical corporations from paying generic drug competitors to delay releasing their cheaper versions of brand-name drugs. They argue these deals deny American consumers, usually for years, steep price declines.
The court case poses the question of an Indiana farmer’s actions violated the patent rights held by Monsanto, which developed seeds that survive when farmers spray their fields with Roundup weed-killer. The seeds dominate agriculture, including in Indiana, where more than 90 percent of soybeans are Roundup Ready.
Universities that once focused on faculty inventions now are encouraging students to pursue patents. Last year, 355 Purdue University students filed a patent, a 62-percent jump from 218 student-filed patents the previous year.
The unsuccessful lawsuit filed by a subsidiary of Belgium-based Bayer Bioscience claimed that insect-resistant corn products from affiliates of Dow AgroSciences violated two of its patents.
The lawsuit, filed in December 2010 by Bayer CropScience SA, charged that Indianapolis-based Dow AgroSciences’ herbicide-tolerance technology infringed one of its patents.
For Indiana’s life sciences sector, the change both raises hopes and creates challenges for continued growth.
The Indianapolis-based pharmaceutical firm claims an Australian veterinary clinic is infringing on its Comfortis flea medication’s trademark by reselling it to U.S. consumers online.
BorgWarner Inc., the world’s biggest maker of automatic-transmission parts for vehicles, filed a lawsuit accusing Cummins Inc. of infringing on three patents for a titanium wheel used in engine turbochargers.
When the Senate passed legislation last week overhauling the U.S. patent system, large multinational corporations like Eli Lilly and Co. rejoiced. But small-business advocates cried foul, saying the changes would put innovative startups at a disadvantage.
Remember Effient? The blood thinner that was once Eli Lilly and Co.’s greatest post-Zyprexa hope and then, after a slow launch, was dismissed as an abject failure? Well, it’s turning out to defy both predictions.